Oragenics Inc.
OGEN
OGEN: Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
moreShow OGEN Financials
Recent trades of OGEN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OGEN's directors and management
Government lobbying spending instances
-
$10,000 Jul 19, 2021 Issue: Defense
-
$10,000 Apr 20, 2021 Issue: Defense
-
$50,000 Nov 02, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$50,000 Oct 20, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$40,000 Jul 20, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$10,000 Jan 19, 2011 Issue: None
-
$10,000 Oct 18, 2010 Issue: Health Issues
-
$10,000 Jul 19, 2010 Issue: Health Issues
-
$10,000 Apr 16, 2010 Issue: Budget/Appropriations
New patents grants
Federal grants, loans, and purchases
Followers on OGEN's company Twitter account
Number of mentions of OGEN in WallStreetBets Daily Discussion
Recent insights relating to OGEN
Recent picks made for OGEN stock on CNBC
ETFs with the largest estimated holdings in OGEN
Flights by private jets registered to OGEN